Investigational drug · Phase 2
ION717
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Prion Disease.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "ION717"
First trial start
2024
Jan 4, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ION717", any sponsor or status.
Conditions studied
As listed on its trial records.
- Prion Disease
Largest trials
Live from ClinicalTrials.gov: studies naming "ION717" as an intervention, largest first.
- PrProfile: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ION717Active, not recruiting
Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals (IONS)
NCT06153966 · 85 participants · Start Jan 4, 2024 · Primary completion Apr 2027
Drug: ION717; Placebo · For: Prion Disease
Sites: Boston, Massachusetts; New York, New York; Cleveland, Ohio · 13 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Therapeutic Trajectories in Human Prion Diseases.
Barreca ML, Biasini E · Subcell Biochem 2025
Also in development for Prion Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Ionis Pharmaceuticals.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.